Navigation Links
NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/26/2008

Highlights:

-- NDA filing for dermal patch NGX-4010 in PHN expected in 2008 -- IND filing for liquid formulation NGX-1998 expected in first half of

2008

-- NGX-4010 MAA under EMEA review for neuropathic pain

-- Closed $25 million private placement

SAN MATEO, Calif., March 26 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported financial results for the fourth quarter and full year ended December 31, 2007.

Anthony DiTonno, President and Chief Executive Officer, commented, "2007 was a positive year for NeurogesX in terms of moving our product candidates forward and achieving numerous key milestones. In September, we announced positive results from our second Phase 3 trial of our dermal patch drug candidate, NGX-4010, in postherpetic neuralgia (PHN). We expect to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) later this year in PHN. Additionally, we are continuing with the marketing authorization application (MAA) under the centralized procedure in the European Union, where our application was accepted by the European Medicines Agency (EMEA) in September 2007. We are evaluating our development program in painful diabetic neuropathy (PDN) and our clinical and regulatory strategies with regard to the painful HIV-distal sensory polyneuropathy (HIV-DSP) indication, in light of our recent Phase 3 trial in HIV-DSP that did not meet its primary endpoint. We remain on track to file an investigational new drug application (IND) for our high concentration capsaicin liquid fo
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007
2. NeurogesX to Present at RBC Capital Markets 2007 Healthcare Conference
3. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. Haemacure Reports Third Quarter 2007 Results
6. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
7. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
8. MDS Reports Third Quarter 2007 Results
9. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... (PRWEB) September 23, 2014 "The primary purpose ... control," said an inventor from Sacramento, Ca.. "Call lights are ... or left hanging on the IV pole out of the ... the nurse call device whenever they need it, I created ... effectively position the nurse call device within easy reach. The ...
(Date:9/23/2014)... Davis, and Academia Sinica, the preeminent academic institution ... into a collaborative agreement to develop a unique ... research with opportunities to translate innovative technologies and ... agreement was signed Sept.12 in Taipei by Harris ... and President Chi-Huey Wong of Academia Sinica. The ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... 5, that its Private Label Jalapeno Bagels are recalled ... stones. Publix Jalapeno Bagels were sold in ... department. , Taking into consideration the latest developments, ...
(Date:9/23/2014)... Kathleen Doheny HealthDay Reporter ... at very low birth weights, breast milk is more likely ... infection known as cytomegalovirus (CMV), a new study finds. ... infants -- all of whom weighed 3.3 pounds or less ... of CMV infection, to see whether breast milk or transfusions ...
(Date:9/23/2014)... 2014 (HealthDay News) -- Both drinking and getting drunk ... alcohol abuse by high school students, a new study ... high school students who drink, could help expand alcohol-prevention ... drink, to stop them from becoming binge drinkers, the ... of first alcohol use and progression to first heavy ...
Breaking Medicine News(10 mins):Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 3
... Reactors Could Solve the Isotope Crisis within 24 months ... Nordion, a leading provider of medical isotopes and radiopharmaceuticals, ... Expert Review Panel on Medical Isotope and Technetium-99m (Tc-99m) ... to the shortage of medical radioisotopes is the completion ...
... male and seven female) with hepatic angiomyolipoma, with a ... Of these patients, dynamic contrast CT showed hepatic angiomyolipoma ... of a capsule, and prominent central vessels in six ... without a fat component in four cases with tuberous ...
... , DENVER July 30 Air Methods Corporation ... quarter ended June 30, 2009 after the close of the market on ... for Thursday, August 6, 2009 at 4:15 p.m. Eastern to discuss these ... the call by dialing (877) 883-0656 (domestic) or (706) 643-8826 (international) or ...
... , PLEASANTON, Calif., July 30 TriReme ... second product, a novel coronary dilatation catheter, designed to improve ... near side branches. The product will be marketed under the ... a first-in-class balloon dilatation catheter with a torquable shaft and ...
... centers didn,t increase weight, study found , THURSDAY, July 30 ... else,s home, they,re more likely to be heavier than average ... researchers report in the August issue of Pediatrics ... for in someone else,s home, rather than in their own ...
... WILMINGTON, Del., July 30 AstraZeneca (NYSE: ... a New Drug Application to the U.S. Food and Drug ... European Medicines Agency (EMEA) for an investigational drug, vandetanib 100 ... of advanced non-small cell lung cancer in patients previously treated ...
Cached Medicine News:Health News:MDS Nordion Submits Expression of Interest Proposal to Government of Canada on Medical Isotope and Generator Production 2Health News:MDS Nordion Submits Expression of Interest Proposal to Government of Canada on Medical Isotope and Generator Production 3Health News:TriReme Medical, Inc. Receives CE Marking for Glider(TM) PTCA Dilatation Catheter 2Health News:Infants Cared for in Another Home Become Heavier Toddlers 2Health News:Infants Cared for in Another Home Become Heavier Toddlers 3Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 2Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 3Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 4
(Date:9/23/2014)... This test can detect HIV infection if used ... by activities that can transfer body fluids from one person ... shared needles. , An in-vitro diagnostic home-use test ... test works by looking for your body,s response to fighting ... enabling patients to learn their status in a single visit ...
(Date:9/23/2014)... Research and Markets has announced the addition ... report to their offering. Though biotechnology ... products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders ... stages of clinical drug testing for new biopharmaceuticals, as ... to upscale while anticipating FDA or EMA approval. During ...
(Date:9/23/2014)... FRANCISCO , Sept. 23, 2014  SiteOne Therapeutics ... of equity financing. Led by Sears Capital Management and ... Joe Zakrzewski , the $1.5 million financing positions ... program for pain and to further develop its technology ... pain indications. In conjunction with the financing, ...
Breaking Medicine Technology:WholeHealth Products announces the release of the FDA Cleared "HIV 1&2" Rapid Diagnostic Test for Professional and Retail 2Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3
... HeartSine Technologies, Inc. was honored with the ... 50 event in Stormont, Belfast. The award was presented to ... pioneering business in developing areas of Belfast, Ireland. ... the Long Gallery in Stormont on behalf of HeartSine, said, ...
... N.Y., Oct. 11 Dr. Joan Fallon, founder and CEO ... research and development company focused on the treatment of neurological ... Life Sciences Summit 2010, held September 22-23 in Hauppauge, New ... New York at Stony Brook, Brookhaven National Laboratories and Cold ...
Cached Medicine Technology:HeartSine Technologies Honored With Belfast Ambassador Award at Belfast Business Top 50 Event 2Curemark Moderates Autism Panel at Life Sciences Summit 2010 2Curemark Moderates Autism Panel at Life Sciences Summit 2010 3
... ALLEGRO Topolyzer and T-CAT have been optimized ... vision correction and to interact in perfect ... systems. All necessary treatment and patient parameters ... the ALLEGRETTO WAVE laser systems via diskette, ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
Medicine Products: